ClinicalTrials.gg
Sign In
Drug

Sintilimab clinical trials

Also written IBI308.

studies test it
401
open now
215
in phase 3
48
first study started
2016

How each study uses sintilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sintilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sintilimab
236
Tyvyt
16
Sintilimab Injection
10
PD-1 antibody
5
Sintilimab plus Chemotherapy
4

Development codes

IBI308
61

In one entry with another drug

Given together, or one or the other

sintilimab combined with anlotinib
3
Anlotinib plus Sintilimab
2
fruquintinib + sintilimab + SOX
2
neoadjuvant SCRT followed by Sintilimab plus CAPOX
2
Sintilimab Combined With Docetaxel Monotherapy
2
Ipilimumab & Sintilimab
2
Disitamab Vedotin combined with Sintilimab
2

Studies by the year they started

401 studies that test it; most in 2021 (57)

Studies that test sintilimab, by start year
YearStudies
20161
20173
201812
201946
202045
202157
202251
202336
202456
202538
202656

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
48
Phase 2
316
Phase 3
48
Phase 4
4
No phase
16

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Hepatocellular
43
Stomach Neoplasms
39
Carcinoma, Non-Small-Cell Lung
30
Colorectal Neoplasms
20
Esophageal Squamous Cell Carcinoma
20
Rectal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
9
Lung Neoplasms
8
Nasopharyngeal Carcinoma
7
Esophageal Neoplasms
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
4

Who runs them

Industry 40 · Other 361

Sun Yat-sen University (43) · Fudan University (33) · Innovent Biologics (Suzhou) Co. Ltd. (28) · Tianjin Medical University Cancer Institute and Hospital (22) · The First Affiliated Hospital with Nanjing Medical University (11) · Zhejiang Cancer Hospital (11) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (11) · Second Affiliated Hospital, School of Medicine, Zhejiang University (8)

Often tested with

Tested in the same studies.

Lenvatinib (23) · Anlotinib (20) · HMPL-013 (14) · Tucidinostat (13) · Ipilimumab (12) · Bevacizumab (10) · Surufatinib (9) · CAPOX Regimen (8)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Sintilimab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 44, 4 in phase 3

Studies that test sintilimab, phase 3 first.

Studies

Open first, then newest update. How each study uses sintilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 401

See all 401 studies that test sintilimab →

Given beside what is tested · 69 — sintilimab is usual care or a partner of the new treatment

Showing 20 of 69.

As the comparator · 11 — what is tested is compared with sintilimab

Codes

What other systems call sintilimab · ClinicalTrials.gg INT001138

  • MeSH (NLM) C000632826sintilimabOne source NLM
  • UNII (FDA) 8FU7FQ8UPKSINTILIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q63313766sintilimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C132992SintilimabOne source FDA
  • DrugBank DB15765One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.